Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use
Status:
Completed
Trial end date:
2020-04-22
Target enrollment:
Participant gender:
Summary
This study deploys a novel digital pill with Emtricitabine/Tenofovir (TDF/FTC) among MSM with
substance use to monitor PrEP adherence. The investigators will enroll N=15 HIV uninfected
MSM with self reported substance use who are on PrEP or initiating PrEP to use digital pills
over encapsulating TDF/FTC for 3 months. The investigators will assess the feasibility of
using digital pills in this study population as well as understand the acceptability of
digital pills for adherence measurement using semi-structured individual interviews.
Additionally, the investigators will measure adherence over time, as well as episodes of
suboptimal PrEP adherence.
Phase:
Phase 4
Details
Lead Sponsor:
Fenway Community Health Peter Chai
Collaborator:
Gilead Sciences
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination